Part II: Public Payers in the U.S. & Key International Markets

October 3, 2019 4:00 PM - 6:30 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

This event, Part II in a three part series that will explore the value of health, will focus on Medicare and Medicaid in the U.S., existing access and reimbursement issues for innovative therapies and cures, proposed changes to those programs that could impact access and reimbursement, and barriers that exist to innovative payment models. The event will also consider those key international models of assessing value and determining access, how the global landscape is shifting, what the U.S. may be able to learn from them, and highlight emerging markets like China that are moving toward the realm of “must consider” when developing an international strategy. Speakers will share lessons learned and case studies around:

  • How Louisiana Medicaid cured its Hepatitis C population through an innovative payment model with Gilead Sciences 
  • How Biogen and Alnylam approached approvals abroad; lessons learned for navigating health technology assessment (HTA) consolidation in Europe
  • Why a US biotech partnered with a Chinese company to reach the large patient populations in China

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. Download the Part II whitepaper

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email

Vice President, Global Public Policy & Government Relations, Alnylam Pharmaceuticals
Alan Eisenberg is Vice President, Global Public Policy & Government Relations at Alnylam. In addition to global policy and government relations, he also leads US public payer engagement and reimbursement strategies, as well as government pricing. Prior to Alnylam, Eisenberg federal government relations for Celgene and was Executive Vice President at the Biotechnology Innovation Organization (BIO). He has served in a variety of senior staff and policy making roles on Capitol Hill and was a key member of staff teams that wrote several significant health laws including pediatric exclusivity, Medicare Part B reimbursement (Average Sales Price), and the creation of Medicare Part D. Eisenberg also worked at Ford Motor Company in Dearborn, MI, as an economist and finance manager. Eisenberg holds masters degrees from Harvard and George Washington Universities, and a Bachelor of Science from Union College.